BMRN Q4 2020 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$452M-0.5% YoY

Gross Profit

$326M72.1% margin

Operating Income

-$45M-9.9% margin

Net Income

$22M4.9% margin

EPS (Diluted)

$0.12

QoQ Revenue Growth

-5.2%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$44M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$5.8B

Total Liabilities

$1.7B

Stockholders' Equity

$4.1B

Cash & Equivalents

$649M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$452M	$454M	-0.5%
Gross Profit	$326M	$359M	-9.1%
Operating Income	-$45M	-$9M	-389.4%
Net Income	$22M	$15M	+47.1%

Revenue Segments

Product

$437M97%

Royalty And Other

$15M3%

Geographic Segments

UNITED STATES

$183M40%

Europe

$143M32%

Latin America

$64M14%

Rest Of World

$62M14%